B‑cell lymphoma 2 is associated with advanced tumor grade and clinical stage, and reduced overall survival in young Chinese patients with colorectal carcinoma

Wang,Jiasheng; He,Gan; Yang,Qiang; Bai,Lian; Jian,Bin; Li,Qugang; Li,Zhongfu

doi:10.3892/ol.2018.8489

B‑cell lymphoma 2 is associated with advanced tumor grade and clinical stage, and reduced overall survival in young Chinese patients with colorectal carcinoma

Authors:
- Jiasheng Wang
- Gan He
- Qiang Yang
- Lian Bai
- Bin Jian
- Qugang Li
- Zhongfu Li
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Yongchuan Hospital, Chongqing Medical University, Chongqing 402160, P.R. China, Department of Gastrointestinal Surgery, Chongqing Emergency Medical Center, Center Hospital of Chongqing University, Chongqing 400014, P.R. China
Published online on: April 13, 2018 https://doi.org/10.3892/ol.2018.8489
Pages: 9009-9016
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development of biomarkers that accurately and reliably detect colorectal cancer is a promising approach for colorectal cancer screening. Therefore, the objective of the present study was to evaluate the protein expression of α‑methylacyl‑CoA racemase (P504S/AMACR), tumor protein p53 (p53), B‑cell lymphoma 2 (Bcl‑2) and Ki‑67/mindbomb E3 ubiquitin protein ligase 1 (MIB‑1) in a population of Chinese patients with colorectal carcinoma. Colorectal tumors with matched normal tissue margins were collected from 148 surgical patients, and the demographic and clinical characteristics were collected. Immunohistochemical staining and western blot analysis of P504S/AMACR, p53, Bcl‑2 and Ki‑67/MIB‑1 were conducted. Statistical analyses were used to compare protein expression in the colorectal tumors and matched normal tissue margins and to identify any associations between them and various clinicopathological parameters. Survival analyses were performed using the Kaplan‑Meier method. In the present study, immunohistochemistry and western blot analysis revealed significantly higher expression of all four proteins in colorectal tumors compared with matched normal tissue margins (P<0.001). Spearman's rank correlation analysis revealed that Bcl‑2 expression was negatively correlated with pathological grade and Tumor‑Node‑Metastasis (TNM) stage (‑0.827 and ‑0.388, respectively; P<0.05). Bcl‑2 expression was revealed to be a significant prognostic indicator of colorectal carcinoma [relative risk (95% CI), 0.703 (0.552‑0.895); P<0.05]. The log‑rank test revealed a significant association between low Bcl‑2 expression and reduced overall survival (P=0.039), as well as a significant association between older age (>55 years) and reduced overall survival (P<0.001) in Chinese patients with colorectal carcinoma. In conclusion, low expression of Bcl‑2 is significantly correlated with advanced pathological grade and TNM stage and is a prognostic indicator of reduced overall survival in young Chinese patients with colorectal carcinoma.

View Figures

View References

1	Bray F, Ren JS, Masuyer E and Ferlay J: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sung JJ, Lau JY, Goh KL and Leung WK: Asia Pacific Working Group on Colorectal Cancer: Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
3	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
4	Coghlin C and Murray GI: Biomarkers of colorectal cancer: Recent advances and future challenges. Proteomics Clin Appl. 9:64–71. 2015. View Article : Google Scholar : PubMed/NCBI
5	Coghlin C and Murray GI: Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics. 13:2227–2228. 2013. View Article : Google Scholar : PubMed/NCBI
6	Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, Welch R, Huang WY and Hayes RB: Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 16:1536–1542. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR, et al: alpha-Methylacyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol. 161:841–848. 2002. View Article : Google Scholar : PubMed/NCBI
8	Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
9	Oshima CT, Iriya K and Forones NM: Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma. 52:420–424. 2005.PubMed/NCBI
10	Dawson DA, Grant BF, Stinson FS and Zhou Y: Effectiveness of the derived alcohol use disorders identification test (AUDIT-C) in screening for alcohol use disorders and risk drinking in the US general population. Alcohol Clin Exp Res. 29:844–854. 2005. View Article : Google Scholar : PubMed/NCBI
11	Haining Z, Kawai N, Miyake K, Okada M, Okubo S, Zhang X, Fei Z and Tamiya T: Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas. BMC Clin Pathol. 12:42012. View Article : Google Scholar : PubMed/NCBI
12	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
13	Goel MK, Khanna P and Kishore J: Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 1:274–278. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kelly PN and Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
15	Strasser A, O'Connor L and Dixit VM: Apoptosis signaling. Annu Rev Biochem. 69:217–245. 2000. View Article : Google Scholar : PubMed/NCBI
16	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
17	Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, et al: Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets. 17:61–75. 2013. View Article : Google Scholar : PubMed/NCBI
18	Hague A, Moorghen M, Hicks D, Chapman M and Paraskeva C: BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene. 9:3367–3370. 1994.PubMed/NCBI
19	Biden KG, Simms LA, Cummings M, Buttenshaw R, Schoch E, Searle J, Gobe G, Jass JR, Meltzer SJ, Leggett BA and Young J: Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. Oncogene. 18:1245–1249. 1999. View Article : Google Scholar : PubMed/NCBI
20	Shanmugam C, Katkoori VR, Jhala NC, Grizzle WE, Siegal GP and Manne U: p53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior. J Histochem Cytochem. 56:305–312. 2008. View Article : Google Scholar : PubMed/NCBI
21	Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Tötsch M, Böcker W, Jasani B and Schmid KW: Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 72:981–985. 1995. View Article : Google Scholar : PubMed/NCBI
22	Baretton GB, Diebold J, Christoforis G, Vogt M, Müller C, Dopfer K, Schneiderbanger K, Schmidt M and Löhrs U: Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer. 77:255–264. 1996. View Article : Google Scholar : PubMed/NCBI
23	Sinicrope FA, Hart J, Michelassi F and Lee JJ: Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1:1103–1110. 1995.PubMed/NCBI
24	Bhatavdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI, Suthar TP, Doctor SS, Shah NG and Balar DB: Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum. 40:785–790. 1997. View Article : Google Scholar : PubMed/NCBI
25	Bukholm IK and Nesland JM: Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 436:224–228. 2000. View Article : Google Scholar : PubMed/NCBI
26	Bosari S, Moneghini L, Graziani D, Lee AK, Murray JJ, Coggi G and Viale G: bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol. 26:534–540. 1995. View Article : Google Scholar : PubMed/NCBI
27	Tollenaar RA, van Krieken JH, van Slooten HJ, Bruinvels DJ, Nelemans KM, van den Broek LJ, Hermans J and van Dierendonck JH: Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: No evidence for prognostic significance. Br J Cancer. 77:1842–1847. 1998. View Article : Google Scholar : PubMed/NCBI
28	Kaklamanis L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I, Biddolph S, Tsiotos P, Mortensen N, Gatter KC and Harris AL: Bcl-2 protein expression: Association with p53 and prognosis in colorectal cancer. Br J Cancer. 77:1864–1869. 1998. View Article : Google Scholar : PubMed/NCBI
29	Matkowskyj KA, Chen ZE, Rao MS and Yang GY: Dysplastic lesions in inflammatory bowel disease: Molecular pathogenesis to morphology. Arch Pathol Lab Med. 137:338–350. 2013. View Article : Google Scholar : PubMed/NCBI